FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014351500> ?p ?o ?g. }

• W2014351500 endingPage "1543" @default.
• W2014351500 startingPage "1519" @default.
• W2014351500 abstract "Fluarix® is a trivalent, inactivated, split-virion influenza vaccine containing 15 μg haemagglutinin from each of the three influenza virus strains (including an H1N1 influenza A virus subtype, an H3N2 influenza A virus subtype and an influenza B virus) that are expected to be circulating in the up-coming influenza season. Fluarix® is highly immunogenic in healthy adults and elderly, and exceeds the criteria that make it acceptable for licensure in various regions (including the US and Europe). In a large, phase III, placebo-controlled, double-blind trial conducted in the US (2004/2005) in subjects aged 18–64 years, postvaccination sero-conversion rates against the H1N1, H3N2 and B antigens were 60–78% and respective postvaccination seroprotection rates were 97–99% in Fluarix® recipients. Another phase III trial conducted in the US (2005/2006) established the noninferiority of Fluarix® versus another trivalent inactivated influenza virus vaccine in subjects aged ≥18 years, including a subgroup of elderly subjects. In annual European registration trials, Fluarix® has consistently exceeded the immunogenicity criteria set by the EU Committee for Medicinal Products for Human Use for adults and the elderly. Fluarix® demonstrated immunogenicity in small, open-label studies in at-risk subjects. During a year when the vaccine was well matched to the circulating strain, Fluarix® demonstrated efficacy against culture-confirmed influenza A and/or B in a placebo-controlled trial in adults aged 18–64 years. In addition, Fluarix® vaccination of pregnant women demonstrated efficacy in reducing the rate of laboratory-confirmed influenza in the infants and reducing febrile respiratory illnesses in the mothers and their new-born infants in a randomized trial. Fluarix® was generally well tolerated in adults and the elderly in well designed clinical trials and in the annual European registration trials, with most local and general adverse events being transient and mild to moderate in intensity. The most common adverse reactions in recipients of Fluarix® were pain, redness or swelling at the injection site, muscle aches, fatigue, headache and arthralgia. In conclusion, Fluarix® is an important means of decreasing the impact of seasonal influenza viruses on adults and the elderly." @default.
• W2014351500 created "2016-06-24" @default.
• W2014351500 creator A5028880152 @default.
• W2014351500 creator A5035386661 @default.
• W2014351500 date "2010-08-01" @default.
• W2014351500 modified "2023-10-15" @default.
• W2014351500 title "Inactivated Split-Virion Seasonal Influenza Vaccine (Fluarix®)" @default.
• W2014351500 cites W1101707968 @default.
• W2014351500 cites W1967771379 @default.
• W2014351500 cites W1970099748 @default.
• W2014351500 cites W1970848116 @default.
• W2014351500 cites W1972178773 @default.
• W2014351500 cites W1974031846 @default.
• W2014351500 cites W1978586676 @default.
• W2014351500 cites W1980741538 @default.
• W2014351500 cites W1983804044 @default.
• W2014351500 cites W1984986413 @default.
• W2014351500 cites W1985096125 @default.
• W2014351500 cites W1987328536 @default.
• W2014351500 cites W1995814039 @default.
• W2014351500 cites W1998015416 @default.
• W2014351500 cites W2008361529 @default.
• W2014351500 cites W2010107685 @default.
• W2014351500 cites W2014289441 @default.
• W2014351500 cites W2014786815 @default.
• W2014351500 cites W2016605117 @default.
• W2014351500 cites W2031193236 @default.
• W2014351500 cites W2031809616 @default.
• W2014351500 cites W2033644132 @default.
• W2014351500 cites W2035281748 @default.
• W2014351500 cites W2036759035 @default.
• W2014351500 cites W2037489349 @default.
• W2014351500 cites W2047477823 @default.
• W2014351500 cites W2048801060 @default.
• W2014351500 cites W2052906913 @default.
• W2014351500 cites W2054770708 @default.
• W2014351500 cites W2058144955 @default.
• W2014351500 cites W2058312037 @default.
• W2014351500 cites W2059044331 @default.
• W2014351500 cites W2060873578 @default.
• W2014351500 cites W2063554346 @default.
• W2014351500 cites W2067819852 @default.
• W2014351500 cites W2071657440 @default.
• W2014351500 cites W2076620856 @default.
• W2014351500 cites W2078694630 @default.
• W2014351500 cites W2079945972 @default.
• W2014351500 cites W2080582088 @default.
• W2014351500 cites W2080855765 @default.
• W2014351500 cites W2090634289 @default.
• W2014351500 cites W2090790452 @default.
• W2014351500 cites W2090937933 @default.
• W2014351500 cites W2091526576 @default.
• W2014351500 cites W2093904246 @default.
• W2014351500 cites W2095069717 @default.
• W2014351500 cites W2095867033 @default.
• W2014351500 cites W2097222403 @default.
• W2014351500 cites W2107587363 @default.
• W2014351500 cites W2107982464 @default.
• W2014351500 cites W2112337023 @default.
• W2014351500 cites W2119611042 @default.
• W2014351500 cites W2121708957 @default.
• W2014351500 cites W2122868020 @default.
• W2014351500 cites W2124834066 @default.
• W2014351500 cites W2126353630 @default.
• W2014351500 cites W2127354472 @default.
• W2014351500 cites W2127890221 @default.
• W2014351500 cites W2131087941 @default.
• W2014351500 cites W2133319531 @default.
• W2014351500 cites W2135396955 @default.
• W2014351500 cites W2136123493 @default.
• W2014351500 cites W2139633093 @default.
• W2014351500 cites W2139738904 @default.
• W2014351500 cites W2145391953 @default.
• W2014351500 cites W2147193679 @default.
• W2014351500 cites W2148989218 @default.
• W2014351500 cites W2149223126 @default.
• W2014351500 cites W2152015613 @default.
• W2014351500 cites W2160128556 @default.
• W2014351500 cites W2167620733 @default.
• W2014351500 cites W2167841507 @default.
• W2014351500 cites W2171955818 @default.
• W2014351500 cites W2209977920 @default.
• W2014351500 cites W4237236497 @default.
• W2014351500 doi "https://doi.org/10.2165/11205020-000000000-00000" @default.
• W2014351500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20687619" @default.
• W2014351500 hasPublicationYear "2010" @default.
• W2014351500 type Work @default.
• W2014351500 sameAs 2014351500 @default.
• W2014351500 citedByCount "9" @default.
• W2014351500 countsByYear W20143515002012 @default.
• W2014351500 countsByYear W20143515002013 @default.
• W2014351500 countsByYear W20143515002014 @default.
• W2014351500 countsByYear W20143515002016 @default.
• W2014351500 countsByYear W20143515002021 @default.
• W2014351500 crossrefType "journal-article" @default.
• W2014351500 hasAuthorship W2014351500A5028880152 @default.
• W2014351500 hasAuthorship W2014351500A5035386661 @default.
• W2014351500 hasBestOaLocation W20143515001 @default.

• next